Literature DB >> 26599540

Copy number variations play important roles in heredity of common diseases: a novel method to calculate heritability of a polymorphism.

Yoshiro Nagao1,2,3.   

Abstract

"Missing heritability" in genome wide association studies, the failure to account for a considerable fraction of heritability by the variants detected, is a current puzzle in human genetics. For solving this puzzle the involvement of genetic variants like rare single nucleotide polymorphisms (SNPs) and copy number variations (CNVs) has been proposed. Many papers have published estimating the heritability of sets of polymorphisms, however, there has been no paper discussing the estimation of a heritability of a single polymorphism. Here I show a simple but rational method to calculate heritability of an individual polymorphism, hp(2). Using this method, I carried out a trial calculation of hp(2) of CNVs and SNPs using published data. It turned out that hp(2) of some CNVs is quite large. Noteworthy examples were that about 25% of the heritability of type 2 diabetes mellitus and about 15% of the heritability of schizophrenia could be accounted for by one CNV and by four CNVs, respectively. The results suggest that a large part of missing heritability could be accounted for by re-evaluating the CNVs which have been already found and by searching novel CNVs with large hp(2).

Entities:  

Mesh:

Year:  2015        PMID: 26599540      PMCID: PMC4657159          DOI: 10.1038/srep17156

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Genome-wide association studies (GWAS) have identified hundreds of gene polymorphisms associated with common diseases, however, every effort to explain the heritability of a disease by single nucleotide polymorphisms (SNPs) detected in GWAS has been failed123. Wellcome Trust Case Control Consortium et al. reported a genome-wide association study of copy number variations (CNVs) for eight common diseases in 2010, and they concluded that common CNVs that can be typed on existing platforms are unlikely to contribute greatly to the genetic basis of common human diseases4. Because efforts have largely focused on common genetic variants, one hypothesis is raised that much of the missing heritability is due to rare genetic variants25. However, it has not yet reported that a large part of the heritability of a disease is accounted for by rare variants. Although many papers have reported the contribution of a set of variants to heritability by the quantitative genetic analysis, there has been no paper discussing about the estimation of a heritability of a single polymorphism. Here I describe a novel method to calculate heritability of an individual polymorphism including a SNP or a CNV.

Results

Definitions and premises

The frequency of a risk allele in a general population: p. The frequency of non-risk allele in a general population: q. The frequency of a risk allele in patients: u. The frequency of non-risk allele in patients: v. The prevalence of a disease: P. Suppose frequencies of the risk and non-risk alleles of asymptomatic individuals are represented by x and y, respectively, then the following relationships are generated: Odds ratio, OR, is represented by the following: In the reports of case-control study, u, x, and OR are usually shown, and p can be calculated by using Equation [1]. When the data of p and OR are available in a SNP database, u or v should be calculated. It is impossible to have reasonable solutions of u and v using Equations [1, 2, 3]. Instead, they can be estimated by approximated solutions. First of all, calculation of genotype frequencies of the first-degree relatives is necessary for the estimation of heritability. For this purpose, Bayes’ method will be needed, because frequency of the risk genotype(s) of them should be calculated with a posterior probability. For these purposes the following definitions are needed. A and a represent dominant and recessive allele, respectively. The genotype frequency of AA for the proband: α. The genotype frequency of Aa for the proband : β. The genotype frequency of aa for the proband: γ. The frequency of the risk genotype(s) of the general population: X1. The frequency of the risk genotype(s) of the first-degree relatives: Y1. The probability of each genotype for a sibling and an offspring is shown in Table 1. The probability of each genotype for a parent, that is same as for an offspring, is omitted here. The calculation procedure to have genotype probabilities were shown in the section of the methods.
Table 1

Probability of each genotype of a sibling and an offspring.

GenotypeProbability
 Sibling
AA{α(1 + p)2 + βp(1 + p) + γp2}/4
Aa{α(1 + p)q + β(1 + pq) + γp(1 + q)}/2
aa{αq2 +β(1 + q)q + γ(1 + q)2}/4
 Offspring
AAαp + βp/2
Aaαq + β/2 + γp
aaβq/2 + γq

A and a represent dominant and recessive allele, respectively. α, β and γ represent the genotype frequency of AA, Aa and aa of the proband, respectively.

Then the calculations of the heritability of a polymorphism of the main subject are shown.

Heritability of a polymorphism under an autosomal dominant (AD) model

When genotypes AA and Aa have a same risk effect, Y1 of a sibling is calculated using the expressions in Table 1 as follows: Y1 of an offspring is calculated as follows: A relation between the arithmetic mean and the geometrical average indicates that there is a relation of YO1 > YS1 unless v equals to q. Let us think about the incidence rate of the disease among the first-degree relatives, Q. When a polymorphism is involved in a part of the patients group, its share in the prevalence, P, is represented by the population attributable risk that is denoted by P(1–v/q) (Fig. 1A). Suppose that the risk allele of a polymorphism is the only genetic cause of a disease. For the first-degree relatives of the patients who do not have the risk allele the incident rate is not different from that in the general population. Therefore Q will be bigger than P by (Y1/X1 − 1) for the effect of this polymorphism (Fig. 1B). Then the incidence rate of the disease for a sibling, Q, is represented by Equation [6], as follows:
Figure 1

Schematic images of the prevalence of a disease in general population, P, and the incidence rate of the disease for first-degree relatives, Q, for a polymorphism.

(A) P is represented by a circle. The area where the population attributable risk of a polymorphism, P(1–v/q), covers is applied gray. (B) Q is represented by the area where either the circle or the gray oval covers. Q is bigger than P by P(1−v/q)(Y1/X1−1). q: allele frequency of the non-risk allele for the general population. v: allele frequency of the non-risk allele for the patient group. X: frequency of the risk genotype of the general population. Y: frequency of the risk genotype of the first-degree relatives.

The incidence rate for an offspring, Q, is represented by Equation [7], as follows: Once Q or Q is estimated, the heritability of a polymorphism, hp2, is calculated by the Falconer’s liability threshold model6.

Heritability of a polymorphism under an autosomal recessive (AR) model

It is known that some polymorphisms show a recessive effect. If the risk allele of a polymorphism shows a recessive effect, frequencies of the risk genotypes of a sibling and an offspring, YS1 and YO1, are represented as follows, respectively: In the recessive model, homozygote is the risk genotype. Therefore the proportion of patients who have the risk genotype in the holder of risk allele is represented by u2/(u2 + 2uv). The incidence rates of the disease among siblings and among offspring, if we consider only for the effect of the polymorphism are represented by next Equations, respectively, as follows:

Heritability of a polymorphism under other inheritance models

hp2 can be estimated for a polymorphism under any other inheritance models so far the frequency of the risk genotype(s) for the first-degree relatives can be calculated. If a polymorphism is located on an autosome and if the OR of heterozygote is smaller than that of homozygote, the hp2 of this polymorphism is smaller than hp2 under AD model and larger than hp2 under AR model.

Calculation of the heritability of two or more polymorphisms

Falconer’s method is based on the calculation of the “liability thresholds” for the prevalence of a disease in general population and for the recurrence rate in the first-degree relatives. Units of these measures are standard deviations and heritability is estimated by the difference of two measures6. The calculation of the heritability of two or more polymorphisms is possible. For this purpose second clause of Equation [6] or [7] for each polymorphism should be calculated and added finally to P.

Estimation of various CNVs and SNPs reported in the literatures

Most germline CNVs are heritable7. However, heredity form of a CNV is not always known. Furthermore a de novo CNV is sometimes identified in the association studies (3). The heritability of a disease has been often estimated by twin studies. Monozygotic (MZ) twins share all germline polymorphisms including de novo variants, whereas dizygotic (DZ) twins usually do not share a de novo polymorphism. Because heritability is calculated by a difference between the concordance rates of MZ twins and DZ twins, a de novo polymorphism should also be involved in the estimation of heritability in a twin study. When we estimate the contribution of a CNV to the heritability of a disease by Falconer’s model, the recurrence risk to hold the CNV for a sibling cannot be used theoretically because it may be a de novo CNV for the proband. On the other hand, the recurrence risk for an offspring can be used because all germline polymorphisms, including de novo ones, will be fundamentally transmitted to the offspring. Table 2 listed various CNVs and SNPs reported in the literatures. The hp2 of these polymorphisms were calculated for offspring under the AD model. As shown in Table 2, CNVs generally have a larger hp2 (>0.01). A noteworthy result was that about 25% of the heritability of type 2 diabetes mellitus (T2DM) could be accounted for by one CNV, a value greater than the previously estimated heritability explained by all identified variants in GWAS published in 20128. Another noteworthy result was that about 15% of the heritability of schizophrenia could be accounted for by four CNVs, although this value was smaller than the previously estimated heritability (23%) explained by all identified variants in GWAS published in 20129. With regard to schizophrenia, it turned out that the hp2 of a CNV that was detected only in patients (OR = +∞) is large. The results in the analyses suggest that a large part of missing heritability of common diseases could be accounted for by a kind of CNVs. 15q13.3 microdeletions has been reported to be associated not only with schizophrenia but also with idiopathic generalized epilepsy (IGE)210. Although the accurate data of prevalence of IGE that contains several types of epilepsies could not be obtained, hp2 of IGE was estimated to be 0.13–0.15 (not shown in Table 2). CNVs have been suspected to be involved in the pathophysiology of neuropsychiatric conditions11 The results of trial estimation of the hp2 of a polymorphism suggest that CNVs might be the major genetic cause of neuropsychiatric disorders.
Table 2

Results of a trial to calculate hp 2 of CNVs and SNPs using published data.

DiseaseCNV (locus or description) or SNP (rs number or description)Population or sourceORPphp2
AutismCNV* (16p11.2 del)319Americans1000.0060.000160.0679
• CNV (16p11.2 dup)319Americans160.0060.000340.0077
• SNP (rs4307059)20Americans1.190.00670.610.00049
• SNP (rs10513025)21Several sources0.550.0150.0630.0036
Depression• CNV (3q13.33 dup)22Hungarians5.270.0850.0130.0327
• SNP (rs2251219)23(Meta-analysis)0.870.200.400.0014
Schizophrenia• CNV (16p11.2 dup)18Several sources0.010.0000390.0498
• CNV (22q11.2 del)18Several sources0.010.0000350.0377
• CNV (NRXN1 del)18Several sources0.010.0000160.0213
• CNV (AS/PWS dup)18Several sources0.010.0000120.0161
• CNV (15q11.3 del)10Several sources8.270.010.000210.0021
• CNV (1p21.1 del)18Several sources11.030.010.0001750.0019
• SNP (ADAMTSL3)24(HapMap)0.680.010.290.0046
• SNP (rs17504622)25Swedish1.240.010.050.00035
Obsessive-compulsive disorder• CNV (13q14.2 del)26Swiss6.230.0230.0100.0405
• SNP (rs6311, located on HTR2A promoter)26Swiss1.690.0230.440.0087
Sporadic ALS• CNV (10q15.3 dup)27Japanese5.490.00010.1010.0625
• SNP (rs10260404)28Dutch1.300.00010.270.00050
Type 2 diabetes mellitus• CNV (4p16.3 del)29Japanese14.80.100.0220.1594
• SNP (missence variant of HNF1A gene)30Mexicans and US Latinos5.480.140.00600.0146

Odds ratio (OR), risk allele frequency (p), and prevalence of disease (P) of each polymorphism are cited from the literatures31018192021222324252627282930. P of schizophrenia is cited from a review31.

*de novo CNV.

Comparison of the required number of polymorphisms to explain a heritability

Previous studies have estimated the heritability of sets of polymorphisms. Pawitan et al. showed how many variants were needed to explain a heritability of 0.4 in 200912. In order to confirm that the calculated results by using the method described in the present study are consistent with those generated using other approaches, the required numbers of genetic variants under the AD model to explain a heritability of 0.4, when the prevalence of a disease is 0.01, were estimated. In this estimation the additive effect of each hp2 was considered, in the other words, the “narrow sense” heritability was tried to be accounted for. The results by the method in the present study were shown comparing with those of Pawitan et al. in Table 3. The required number of genetic variants calculated using the median of the range of variants in a category was not different from their approximation for the same category except for the common variants of category 1.
Table 3

Various categories of variants and the number of variants to explain heritability of 0.4.

Categories of variants are based on the classification by Pawitan et al.12. The background of the calculated results by the method in this study is applied gray.

Discussion

The estimations of heritability of polymorphisms were mainly conducted for the SNPs that were found in GWAS1231213. It is thought that the heritability of common diseases is due to multiple genes of small effect size and that even qualitative disorders can be interpreted simply as being the extremes of quantitative dimensions, that is, by the quantitative genetic analysis14. Recent studies demonstrated the interaction effects and the collective effects of SNPs in quantitative genetic traits151617. However, I discuss here the conventional quantitative analysis under the premise that there are simple additive effects of polymorphisms. In quantitative genetic analysis authors have assumed a latent susceptibility (or liability) that varies between individuals12. The liability can be due to genetic and environmental factors, and heritability is defined as the proportion of the variance in liability due to genetic factors. For calculation of liability that is contributed by a SNP, OR of allele frequency or OR of risk genotype for a SNP is the fundamental factor for estimating the penetrance in the analysis1213. Therefore when a SNP was detected only in patients (OR = +∞), the calculation is theoretically impossible in the quantitative genetic analysis. After all the quantitative effect of genes with a small effect size is being handled in the analysis and the participation of gene with such a large effect size (OR = +∞) is not assumed. Wellcome Trust Case Control Consortium et al. published in 2010 the estimation of heritability of common CNVs, and they did not take into the consideration for the CNVs that were detected only in patients, either4. However, CNVs are sometimes detected only in the patients as shown in Table 2. In this report a novel method to calculate heritability of a single polymorphism was shown. A trial to estimate the required numbers of genetic variants under the AD model to explain a heritability showed that the calculation results by using the method described in the present study are entirely consistent with those generated by a quantitative genetic analysis (Table 3). I did not introduce the penetrance in the calculation procedure but introduced the population attributable risk that would not be infinity when OR is +∞. By the method in the present report it was suggested that heritability of some CNVs are quite large when it was calculated under the AD model. The heredity form of CNVs is often unknown, and only an OR of allele frequency for a CNV is usually available. Although by the calculation of heritability of CNVs only under the AD model, it was suggested a large part of missing heritability could be accounted for by re-evaluating the CNVs which have been already found and by searching novel CNVs with large hp2. The results of this study also suggest that CNVs might be the major genetic cause of neuropsychiatric disorders. In conclusion, CNVs were turned out to play important roles in familial aggregation of common diseases.

Methods

Calculation of genotype probabilities for a sibling

For the purpose of calculation of genotype probabilities for a sibling, an application of Beye’s method is necessary. An example of the calculation of genotype probabilities by Beye’s method for the father of the proband is shown in Table 4. As a result the posterior probability equals to the frequency of another allele (A or a) of the transmitted one (A) in the general population.
Table 4

An example of the calculation of genotype probabilities by Beye’s method when the genotype of the proband is AA.

 AAAaaa
Prior Probabilitypp2pqqq
Conditioned Probability (of transmitting allele A)10.50
Joint Probabilitypppq0
Posterior Probabilitypp/(pp + pq) = ppq/(pp + pq) = q 

As a result the posterior probability equals to the frequency of another allele (A or a) of the transmitted one (A) in the general population.

Then the genotype probabilities for a sibling are calculated. The calculation procedure of the genotype probabilities for a sibling was shown in Table 5. In Table 5, P1 and P2 are the posterior probabilities of genotypes of father and mother, respectively, and P3 is a conditioned probability of genotype of sibling. A joint probability is the product of F, P1, P2, and P3. The summation of joint probabilities for each genotype was shown in Table 1.
Table 5

The calculation procedure of the genotype probabilities for a sibling.

ProbandFFatherP1MotherP2SiblingP3Joint Probability
AAαAApAApAA1αpp
AaqAA0.50.5αpq
Aa0.50.5αpq
AaqAApAA0.50.5αpq
Aa0.50.5αpq
AaqAA0.250.25αqq
Aa0.50.5αqq
aa0.250.25αqq
AaβAAppAapAA0.50.5βppp
Aa0.50.5βppp
aaqAa1βppq
Aa*pqAapAA0.250.25βppq
Aa0.50.5βppq
aa0.250.25βppq
aaqAa0.50.5βpqq
aa0.50.5βpqq
AapqAApAA0.50.5βppq
Aa0.50.5βppq
AaqAA0.250.25βpqq
Aa0.50.5βpqq
aa0.250.25βpqq
aaqqAApAa1βpqq
AaqAa0.50.5βqqq
aa0.50.5βqqq
aaγAapAapAA0.250.25γpp
Aa0.50.5γpp
aa0.250.25γpp
aaqAa0.50.5γpq
aa0.50.5γpq
aaqAapAa0.50.5γpq
aa0.50.5γpq
aaqaa1γqq

*Allele A is derived from the father.

†Allele a is derived from the father.

F; a frequency of genotype of the proband.

P1; a posterior probability of genotype of father.

P2; a posterior probability of genotype of mother.

P3; a conditioned probability of genotype of sibling.

Calculation of genotype probabilities for an offspring

For calculation of genotype probabilities for an offspring the Beye’s method is not needed. The calculation procedure of the genotype probabilities for an offspring was shown in Table 6. The summation of joint probabilities for each genotype was shown in Table 1.
Table 6

The calculation procedure of the genotype probabilities for an offspring.

ProbandFSpouseP1OffspringP2Joint Probability
AAαAAppAA1αpp
Aa2pqAA0.5αpq
Aa0.5αpq
aaqqAa1αqq
AaβAAppAA0.50.5βpp
Aa0.50.5βpp
Aa2pqAA0.250.5βpq
Aa0.5βpq
aa0.250.5βpq
aaqqAa0.50.5βqq
aa0.50.5βqq
aaγAAppAa1γpp
Aa2pqAa0.5γpq
aa0.5γpq
aaqqaa1γqq

F; a frequency of genotype of the proband.

P1; a probability of genotype of spouse.

P2; a conditioned probability of genotype of offspring.

An example of calculation of heritability of a polymorphism

As an example of a common disease, let us choose schizophrenia. The prevalence, P, of schizophrenia is reported as 0.01. Here, CNV (16p11.2 dup) is chosen as an example of a polymorphism18. The frequency of a risk allele in patients, u, is 0.0039 and the frequency of a risk allele in asymptomatic individuals, x, is 0. Therefore p is calculated as 0.000039 using Equation [1]. By the way, P of schizophrenia (1%) is more than +2.32635SD of a general population. The mean distance from the median in the normal distribution is calculated as +2.6652SD for the patients. The incidence rate under the autosomal dominant model of the disease in a first-degree relative, if we consider only for the effect of the CNV, is represented by Formula [7]: The incidence rate of schizophrenia is calculated as following: This value can be used as a recurrence risk of the disease in first-degree relatives and is more than +2.25998SD. Then heritability (hp2) of CNV (16p11.2 dup) is calculated by Falconer’s liability threshold model, and the result is as following6:

Additional Information

How to cite this article: Nagao, Y. Copy number variations play important roles in heredity of common diseases: a novel method to calculate heritability of a polymorphism. Sci. Rep. 5, 17156; doi: 10.1038/srep17156 (2015).
  30 in total

Review 1.  The genetic equidistance result: misreading by the molecular clock and neutral theory and reinterpretation nearly half of a century later.

Authors:  Taobo Hu; Mengping Long; Dejian Yuan; Zhubing Zhu; Yimin Huang; Shi Huang
Journal:  Sci China Life Sci       Date:  2013-03-23       Impact factor: 6.038

2.  Searching for missing heritability: designing rare variant association studies.

Authors:  Or Zuk; Stephen F Schaffner; Kaitlin Samocha; Ron Do; Eliana Hechter; Sekar Kathiresan; Mark J Daly; Benjamin M Neale; Shamil R Sunyaev; Eric S Lander
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-17       Impact factor: 11.205

3.  ADAMTSL3 as a candidate gene for schizophrenia: gene sequencing and ultra-high density association analysis by imputation.

Authors:  David J Dow; Julie Huxley-Jones; Jamie M Hall; Clyde Francks; Peter R Maycox; James N C Kew; Israel S Gloger; Nalini A L Mehta; Fiona M Kelly; Pierandrea Muglia; Gerome Breen; Sarah Jugurnauth; Inti Pederoso; David St Clair; Dan Rujescu; Michael R Barnes
Journal:  Schizophr Res       Date:  2011-01-15       Impact factor: 4.939

4.  Pilot study on HTR2A promoter polymorphism, -1438G/A (rs6311) and a nearby copy number variation showed association with onset and severity in early onset obsessive-compulsive disorder.

Authors:  Susanne Walitza; Daniel Sabanés Bové; Marcel Romanos; Tobias Renner; Leonhard Held; Michael Simons; Christoph Wewetzer; Christian Fleischhaker; Helmut Remschmidt; Andreas Warnke; Edna Grünblatt
Journal:  J Neural Transm (Vienna)       Date:  2011-08-28       Impact factor: 3.575

5.  Segmental copy-number gain within the region of isopentenyl diphosphate isomerase genes in sporadic amyotrophic lateral sclerosis.

Authors:  Takeo Kato; Mitsuru Emi; Hidenori Sato; Shigeki Arawaka; Manabu Wada; Toru Kawanami; Tadashi Katagiri; Kenji Tsuburaya; Itaru Toyoshima; Fumiaki Tanaka; Gen Sobue; Kenichi Matsubara
Journal:  Biochem Biophys Res Commun       Date:  2010-10-16       Impact factor: 3.575

6.  Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs.

Authors:  S Hong Lee; Teresa R DeCandia; Stephan Ripke; Jian Yang; Patrick F Sullivan; Michael E Goddard; Matthew C Keller; Peter M Visscher; Naomi R Wray
Journal:  Nat Genet       Date:  2012-02-19       Impact factor: 38.330

7.  Analysis of copy number variations at 15 schizophrenia-associated loci.

Authors:  Elliott Rees; James T R Walters; Lyudmila Georgieva; Anthony R Isles; Kimberly D Chambert; Alexander L Richards; Gerwyn Mahoney-Davies; Sophie E Legge; Jennifer L Moran; Steven A McCarroll; Michael C O'Donovan; Michael J Owen; George Kirov
Journal:  Br J Psychiatry       Date:  2013-12-05       Impact factor: 9.319

8.  Genome-wide association analysis identifies 13 new risk loci for schizophrenia.

Authors:  Stephan Ripke; Colm O'Dushlaine; Kimberly Chambert; Jennifer L Moran; Anna K Kähler; Susanne Akterin; Sarah E Bergen; Ann L Collins; James J Crowley; Menachem Fromer; Yunjung Kim; Sang Hong Lee; Patrik K E Magnusson; Nick Sanchez; Eli A Stahl; Stephanie Williams; Naomi R Wray; Kai Xia; Francesco Bettella; Anders D Borglum; Brendan K Bulik-Sullivan; Paul Cormican; Nick Craddock; Christiaan de Leeuw; Naser Durmishi; Michael Gill; Vera Golimbet; Marian L Hamshere; Peter Holmans; David M Hougaard; Kenneth S Kendler; Kuang Lin; Derek W Morris; Ole Mors; Preben B Mortensen; Benjamin M Neale; Francis A O'Neill; Michael J Owen; Milica Pejovic Milovancevic; Danielle Posthuma; John Powell; Alexander L Richards; Brien P Riley; Douglas Ruderfer; Dan Rujescu; Engilbert Sigurdsson; Teimuraz Silagadze; August B Smit; Hreinn Stefansson; Stacy Steinberg; Jaana Suvisaari; Sarah Tosato; Matthijs Verhage; James T Walters; Douglas F Levinson; Pablo V Gejman; Kenneth S Kendler; Claudine Laurent; Bryan J Mowry; Michael C O'Donovan; Michael J Owen; Ann E Pulver; Brien P Riley; Sibylle G Schwab; Dieter B Wildenauer; Frank Dudbridge; Peter Holmans; Jianxin Shi; Margot Albus; Madeline Alexander; Dominique Campion; David Cohen; Dimitris Dikeos; Jubao Duan; Peter Eichhammer; Stephanie Godard; Mark Hansen; F Bernard Lerer; Kung-Yee Liang; Wolfgang Maier; Jacques Mallet; Deborah A Nertney; Gerald Nestadt; Nadine Norton; Francis A O'Neill; George N Papadimitriou; Robert Ribble; Alan R Sanders; Jeremy M Silverman; Dermot Walsh; Nigel M Williams; Brandon Wormley; Maria J Arranz; Steven Bakker; Stephan Bender; Elvira Bramon; David Collier; Benedicto Crespo-Facorro; Jeremy Hall; Conrad Iyegbe; Assen Jablensky; Rene S Kahn; Luba Kalaydjieva; Stephen Lawrie; Cathryn M Lewis; Kuang Lin; Don H Linszen; Ignacio Mata; Andrew McIntosh; Robin M Murray; Roel A Ophoff; John Powell; Dan Rujescu; Jim Van Os; Muriel Walshe; Matthias Weisbrod; Durk Wiersma; Peter Donnelly; Ines Barroso; Jenefer M Blackwell; Elvira Bramon; Matthew A Brown; Juan P Casas; Aiden P Corvin; Panos Deloukas; Audrey Duncanson; Janusz Jankowski; Hugh S Markus; Christopher G Mathew; Colin N A Palmer; Robert Plomin; Anna Rautanen; Stephen J Sawcer; Richard C Trembath; Ananth C Viswanathan; Nicholas W Wood; Chris C A Spencer; Gavin Band; Céline Bellenguez; Colin Freeman; Garrett Hellenthal; Eleni Giannoulatou; Matti Pirinen; Richard D Pearson; Amy Strange; Zhan Su; Damjan Vukcevic; Peter Donnelly; Cordelia Langford; Sarah E Hunt; Sarah Edkins; Rhian Gwilliam; Hannah Blackburn; Suzannah J Bumpstead; Serge Dronov; Matthew Gillman; Emma Gray; Naomi Hammond; Alagurevathi Jayakumar; Owen T McCann; Jennifer Liddle; Simon C Potter; Radhi Ravindrarajah; Michelle Ricketts; Avazeh Tashakkori-Ghanbaria; Matthew J Waller; Paul Weston; Sara Widaa; Pamela Whittaker; Ines Barroso; Panos Deloukas; Christopher G Mathew; Jenefer M Blackwell; Matthew A Brown; Aiden P Corvin; Mark I McCarthy; Chris C A Spencer; Elvira Bramon; Aiden P Corvin; Michael C O'Donovan; Kari Stefansson; Edward Scolnick; Shaun Purcell; Steven A McCarroll; Pamela Sklar; Christina M Hultman; Patrick F Sullivan
Journal:  Nat Genet       Date:  2013-08-25       Impact factor: 38.330

9.  Finding the sources of missing heritability in a yeast cross.

Authors:  Joshua S Bloom; Ian M Ehrenreich; Wesley T Loo; Thúy-Lan Võ Lite; Leonid Kruglyak
Journal:  Nature       Date:  2013-02-03       Impact factor: 49.962

10.  Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes.

Authors:  Andrew P Morris; Benjamin F Voight; Tanya M Teslovich; Teresa Ferreira; Ayellet V Segrè; Valgerdur Steinthorsdottir; Rona J Strawbridge; Hassan Khan; Harald Grallert; Anubha Mahajan; Inga Prokopenko; Hyun Min Kang; Christian Dina; Tonu Esko; Ross M Fraser; Stavroula Kanoni; Ashish Kumar; Vasiliki Lagou; Claudia Langenberg; Jian'an Luan; Cecilia M Lindgren; Martina Müller-Nurasyid; Sonali Pechlivanis; N William Rayner; Laura J Scott; Steven Wiltshire; Loic Yengo; Leena Kinnunen; Elizabeth J Rossin; Soumya Raychaudhuri; Andrew D Johnson; Antigone S Dimas; Ruth J F Loos; Sailaja Vedantam; Han Chen; Jose C Florez; Caroline Fox; Ching-Ti Liu; Denis Rybin; David J Couper; Wen Hong L Kao; Man Li; Marilyn C Cornelis; Peter Kraft; Qi Sun; Rob M van Dam; Heather M Stringham; Peter S Chines; Krista Fischer; Pierre Fontanillas; Oddgeir L Holmen; Sarah E Hunt; Anne U Jackson; Augustine Kong; Robert Lawrence; Julia Meyer; John R B Perry; Carl G P Platou; Simon Potter; Emil Rehnberg; Neil Robertson; Suthesh Sivapalaratnam; Alena Stančáková; Kathleen Stirrups; Gudmar Thorleifsson; Emmi Tikkanen; Andrew R Wood; Peter Almgren; Mustafa Atalay; Rafn Benediktsson; Lori L Bonnycastle; Noël Burtt; Jason Carey; Guillaume Charpentier; Andrew T Crenshaw; Alex S F Doney; Mozhgan Dorkhan; Sarah Edkins; Valur Emilsson; Elodie Eury; Tom Forsen; Karl Gertow; Bruna Gigante; George B Grant; Christopher J Groves; Candace Guiducci; Christian Herder; Astradur B Hreidarsson; Jennie Hui; Alan James; Anna Jonsson; Wolfgang Rathmann; Norman Klopp; Jasmina Kravic; Kaarel Krjutškov; Cordelia Langford; Karin Leander; Eero Lindholm; Stéphane Lobbens; Satu Männistö; Ghazala Mirza; Thomas W Mühleisen; Bill Musk; Melissa Parkin; Loukianos Rallidis; Jouko Saramies; Bengt Sennblad; Sonia Shah; Gunnar Sigurðsson; Angela Silveira; Gerald Steinbach; Barbara Thorand; Joseph Trakalo; Fabrizio Veglia; Roman Wennauer; Wendy Winckler; Delilah Zabaneh; Harry Campbell; Cornelia van Duijn; Andre G Uitterlinden; Albert Hofman; Eric Sijbrands; Goncalo R Abecasis; Katharine R Owen; Eleftheria Zeggini; Mieke D Trip; Nita G Forouhi; Ann-Christine Syvänen; Johan G Eriksson; Leena Peltonen; Markus M Nöthen; Beverley Balkau; Colin N A Palmer; Valeriya Lyssenko; Tiinamaija Tuomi; Bo Isomaa; David J Hunter; Lu Qi; Alan R Shuldiner; Michael Roden; Ines Barroso; Tom Wilsgaard; John Beilby; Kees Hovingh; Jackie F Price; James F Wilson; Rainer Rauramaa; Timo A Lakka; Lars Lind; George Dedoussis; Inger Njølstad; Nancy L Pedersen; Kay-Tee Khaw; Nicholas J Wareham; Sirkka M Keinanen-Kiukaanniemi; Timo E Saaristo; Eeva Korpi-Hyövälti; Juha Saltevo; Markku Laakso; Johanna Kuusisto; Andres Metspalu; Francis S Collins; Karen L Mohlke; Richard N Bergman; Jaakko Tuomilehto; Bernhard O Boehm; Christian Gieger; Kristian Hveem; Stephane Cauchi; Philippe Froguel; Damiano Baldassarre; Elena Tremoli; Steve E Humphries; Danish Saleheen; John Danesh; Erik Ingelsson; Samuli Ripatti; Veikko Salomaa; Raimund Erbel; Karl-Heinz Jöckel; Susanne Moebus; Annette Peters; Thomas Illig; Ulf de Faire; Anders Hamsten; Andrew D Morris; Peter J Donnelly; Timothy M Frayling; Andrew T Hattersley; Eric Boerwinkle; Olle Melander; Sekar Kathiresan; Peter M Nilsson; Panos Deloukas; Unnur Thorsteinsdottir; Leif C Groop; Kari Stefansson; Frank Hu; James S Pankow; Josée Dupuis; James B Meigs; David Altshuler; Michael Boehnke; Mark I McCarthy
Journal:  Nat Genet       Date:  2012-08-12       Impact factor: 38.330

View more
  1 in total

Review 1.  DNA copy number variation: Main characteristics, evolutionary significance, and pathological aspects.

Authors:  Ondrej Pös; Jan Radvanszky; Gergely Buglyó; Zuzana Pös; Diana Rusnakova; Bálint Nagy; Tomas Szemes
Journal:  Biomed J       Date:  2021-02-13       Impact factor: 4.910

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.